RXST Overview

RxSight, Inc. is a commercial-stage medical technology company dedicated to providing customized vision to patients following cataract surgery. The Company's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.

Wall Street analysts forecast RXST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RXST is10.25 USD with a low forecast of 8.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Rxsight Inc revenue for the last quarter amounts to 32.61M USD, decreased -18.91

Rxsight Inc. EPS for the last quarter amounts to -0.22 USD, increased 46.67

Rxsight Inc (RXST) has 461 emplpoyees as of March 03 2026.

Today RXST has the market capitalization of 314.04M USD.